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The impact of hospital volume on cancer pa-
tient outcomes has been firmly established in 
surgical literature including nationwide analyses 
of brain cancer, breast cancer, lung cancer, and 
rectal cancer [1–5]. Recently, investigation of can-
cer patients receiving radiation therapy (RT) has 
demonstrated superior outcomes in high-volume 
centers for glioblastoma and cervical cancer [6, 
7]. However, there has yet to be a volume-based 
survival analysis for the most common tumor of 
the central nervous system (CNS): metastatic dis-
ease. This study is the first to examine the impact 
of hospital volume on survival in metastatic brain 
disease treated with RT. 
AbstrAct
background: The impact of hospital volume on cancer patient survival has been demonstrated in the surgical literature, but 
sparsely for patients receiving radiation therapy (rT). This analysis addresses the impact of hospital volume on patients receiv-
ing rT for the most common central nervous system tumor: brain metastases.  
Materials and methods: analysis was conducted using the National cancer Database (NcDB) from 2010–2015 for patients 
with metastatic brain disease from lung cancer, breast cancer, and colorectal cancer requiring rT. hospital volume was strati-
fied as high-volume (≥ 12 brain rT/year), moderate (5–11 rT/year), and low (< 5 rT/year). The effect of hospital volume on 
overall survival was assessed using a multivariable cox regression model.
results: a total of 18,841 patients [9479 (50.3%) men, 9362 (49.7%) women; median age 64 years] met the inclusion criteria. 
16.7% were treated at high-volume hospitals, 36.5% at moderate-volume, and the remaining 46.8% at low-volume centers. 
Multivariable analysis revealed that mortality was significantly improved in high-volume centers (hr: 0.95, p = 0.039) com-
pared with low-volume centers after accounting for multiple demographics including age, sex, race, insurance status, income, 
facility type, charlson-Deyo score and receipt of palliative care.
conclusion: hospitals performing 12 or more brain rT procedures per year have significantly improved survival in brain 
metastases patients receiving radiation as compared to lower volume hospitals. This finding, independent of additional de-
mographics, indicates that the increased experience associated with increased volume may improve survival in this patient 
population.
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The National Cancer Data Base (NCDB) is a hos-
pital-based cancer registry sponsored jointly by the 
American College of Surgeons and the American 
Cancer Society, and is comprised of more than 1,400 
facilities accredited by the American College of Sur-
geons’ Commission on Cancer (8). The NCDB con-
tains de-identified data on 70% of all newly diag-
nosed cancers in the United States (US) and includes 
data on radiation therapy (i.e. dosage, technique, 
target) not contained in the Surveillance, Epidemiol-
ogy, and End Results (SEER) database [8, 9]. 
Inclusion and exclusion criteria 
The NCDB identified patients with metastatic 
brain disease from lung cancer, breast cancer, and 
colorectal cancer in the US from 2010 through 
2015 having received brain RT (n = 4,053,146). 
We included only patients aged 21 and older, from 
a single reporting facility with a single lifetime neo-
plasm and whose initial diagnosis and first line of 
treatment occurred at that reporting facility. Radia-
tion treatments were limited to 8–3000 cGY total 
dose, which was administered at the reporting fa-
cility. Patients with unknown survival status were 
excluded (n = 19,269, Fig. 1). 
hospital volume
The number of accredited cancer programs in the 
NCDB changes from one diagnosis year to the next, 
meaning not all facilities were accredited for each 
year of the study. We assessed facility accreditation 
using all cases in the Non-Small Cell Lung Cancer 
(NSCLC) database from 2010-2015 (n = 568,683), 
and included only facilities reporting at least one 
case for each year on study. Of the 1,026 originally 
qualified facilities, 995 (97%) reported at least 1 
NSCLC case for each reporting year (n = 18,841 
cases). Hospital volume for treating brain metasta-
ses was annualized as the number of cases between 
2010–2015 divided by the total reporting years 
(n = 6). Facilities were stratified as high (12+ brain 
RT/year), moderate (6–11 RT/year), and low-vol-
ume (0–5 RT/year).  
Data collection
Patient age, sex, income, race, facility type (aca-
demic/research facility, comprehensive cancer 
Figure 1. schematic diagram of exclusion and inclusion criteria based on variables for patients from breast, colon, non-small 
cell lung and small cell lung cancer databases. Number eligible after each selection criterion is provided (n = 19,269). Final 
exclusion required to estimate hospital volume based on facility reporting for each study year was made after compiling the 
dataset. Final number eligible subjects = 18,841
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center, community, integrated network), primary 
payer (Medicare, Medicaid, other government, 
private, no insurance), education (% high school 
graduates in the region), geographic region of the 
US (Northeast, South, Midwest, West), income, 
distance to the treatment facility, primary diag-
nosis, year of primary diagnosis and medical co-
morbidities (the overall comorbidity burden was 
calculated using the Deyo comorbidity index, an 
adapted Charlson comorbidity index) were ana-
lyzed in this study [10, 11]. 
statistical analysis 
R version 3.4.4 (R Foundation; Vienna, Austria) 
was used to perform statistical analyses. Descrip-
tive statistics were used to compare demographic 
and healthcare characteristics of eligible subjects 
based on hospital volume at the primary site, using 
Kruskal-Wallis Test for categorical variables and the 
Mantel-Haenszel Test for Trend for ordinal vari-
ables. Univariate logistic regression was used to 
identify demographic and disease characteristics 
associated with risk of death from metastatic brain 
disease. Due to the size of the dataset all covariates 
achieved a p-value < 0.0001, with several variable 
violating the proportions hazard assumption. Be-
cause of this, we applied the random survival forest 
algorithm (R package random ForestSRC) to a sub-
set of the data (no missing values, n = 19,452) to se-
lect variables most strongly associated with survival 
based on variable importance (VIMP) and Minimal 
Depth calculated over 2000 simulations. Variables 
selected by random survival forest were entered 
into the multivariable model in a stepwise fashion 
first entering hospital volume and then adding sub-
sequent variables based on their strength of associa-
tion (proximity to origin, Fig. 2). Variable selection 
was based on Bayesian Information Criterion (BIC) 
and Akaike’s Information Criterion (AIC). 
results
A total of 18,841 patients (50.3% men, 49.7% 
women; median age 64) met the final inclusion 
criteria. 16.7% were treated at high-volume hospi-
tals, 36.5% at moderate-volume, and the remaining 
46.8% at low-volume centers. Patients who iden-
tified as Black were more likely to be treated at 
a high- or moderate-volume facility than a low-vol-
ume facility (15.8 or 15.1% vs. 11.7%, respectively). 
High-volume facilities were more likely to be locat-
ed in the Northeast (38.8% high-volume vs. 21.6% 
moderate volume vs 18.8% low volume). Based on 
our criteria, no high-volume facilities were identi-
fied in the West. High-volume centers are more 
likely to be academic (74.0% high-volume, 49.1% 
Figure 2. Variable rank by VIMp and Minimal Depth averaged across 2,000 random survival Forest simulations. X-axis: 
selection ranked by variable importance (average change in prediction error in the presence or absence of each variable); 
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moderate-volume, 19.1% low-volume). Twice as 
many patients traveled over 50 miles to be treated 
at a high-volume vs low-volume facility (18.2% vs. 
9.0%). There was little change in proportion of pa-
tients treated by hospital volume facilities over the 
6-year period (Tab. 1).
Results from the univariate analysis are shown 
graphically (Fig. 3). Variables associated with de-
creased risk of death from brain metastases include 
moderate and high hospital volumes (10% and 
18%, respectively), female sex (18%), receiving pal-
liative care (26%), and primary diagnosis of breast 
table 1. patient demographic and healthcare system characteristics by hospital Volume (n = 18,841)
Level Overall Low volume Moderate Volume High volume
N 18841 8824 6869 3148
age [median (IQr)] 64.00 [56.00, 71.00] 65.00 [57.00, 72.00] 63.00 [56.00, 71.00] 62.00 [55.00, 70.00]
sex (%)
Male 9479 (50.3) 4470 (50.7) 3443 (50.1) 1566 (49.7)
Female 9362 (49.7) 4354 (49.3) 3426 (49.9) 1582 (50.3)
race/Hispanic (%)
Nh White 14826 (78.7) 7110 (80.6) 5279 (76.9) 2437 (77.4)
Nh Black 2565 (13.6) 1028 (11.7) 1039 (15.1) 498 (15.8)
hispanic 630 (3.3) 331 (3.8) 208 (3.0) 91 (2.9)
asian/pacific Islander 608 (3.2) 270 (3.1) 273 (4.0) 65 (2.1)
Other/Unknown 212 (1.1) 85 (1.0) 70 (1.0) 57 (1.8)
Annual income (%)
≥ 46,000 UsD 6219 (33.0) 2944 (33.4) 2260 (32.9) 1015 (32.2)
36,000–45,999 UsD 5261 (27.9) 2535 (28.7) 1834 (26.7) 892 (28.3)
30,000–35,999 UsD 3631 (19.3) 1719 (19.5) 1315 (19.1) 597 (19.0)
< 30,000 UsD 3204 (17.0) 1385 (15.7) 1231 (17.9) 588 (18.7)
(Missing) 526 (2.8) 241 (2.7) 229 (3.3) 56 (1.8)
Percent no. High school (%)
< 14% 5418 (28.8) 2541 (28.8) 1994 (29.0) 883 (28.0)
14–19.9% 4448 (23.6) 2183 (24.7) 1560 (22.7) 705 (22.4)
20–28.9% 4852 (25.8) 2269 (25.7) 1732 (25.2) 851 (27.0)
≥ 29% 3595 (19.1) 1589 (18.0) 1353 (19.7) 653 (20.7)
(Missing) 528 (2.8) 242 (2.7) 230 (3.3) 56 (1.8)
Population (%)
Metropolitan, > 250,000 population 14592 (77.4) 6730 (76.3) 5336 (77.7) 2526 (80.2)
Urban 3300 (17.5) 1650 (18.7) 1168 (17.0) 482 (15.3)
rural/Other 533 (2.8) 243 (2.8) 256 (3.7) 34 (1.1)
Missing 416 (2.2) 201 (2.3) 109 (1.6) 106 (3.4)
charlson-Deyo score (%)
0 11853 (62.9) 5516 (62.5) 4261 (62.0) 2076 (65.9)
1 4749 (25.2) 2231 (25.3) 1793 (26.1) 725 (23.0)
2 2239 (11.9) 1077 (12.2) 815 (11.9) 347 (11.0)
Facility type (%)
academic 7392 (39.2) 1689 (19.1) 3372 (49.1) 2331 (74.0)
Integrated Network cancer 2487 (13.2) 1211 (13.7) 745 (10.8) 531 (16.9)
comprehensive cancer center 7610 (40.4) 4667 (52.9) 2657 (38.7) 286 (9.1)
community cancer center 1352 (7.2) 1257 (14.2) 95 (1.4) 0 (0.0)
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cancer (18% compared to NSCLC). Distance from 
the treatment facility did not follow an ordered pro-
tective effect and observed decreased risk of death 
by race may be related to the small sample size.
Variables associated with increased risk of 
death from brain metastases include treatment at 
a non-academic center (41% increase, Community 
Cancer Center, 27% increase for comprehensive 
cancer center). The 10% increase observed at in-
tegrated cancer networks is unclear, given this is 
a mixture of academic and non-academic environ-
ments.  Subjects with Medicare see a 47% increased 
risk of death compared to those with private insur-
ance, although much of this difference is likely at-
tributable to age; those 65 years of age and older are 
at 43% increased risk of death compared to those 
younger than 65 years. As expected, those with in-
creased Charlson-Deyo score are at increased risk 
of death (22% for score = 1, 39% for score at least 2, 
as compared to 0). Subjects living in smaller com-
munities are at higher risk, most likely due to lim-
ited access to treatment (8% for urban centers, 19% 
for rural/other, compared to metropolitan centers) 
and those from the South and Midwest are at great-
table 1. patient demographic and healthcare system characteristics by hospital Volume (n = 18,841)
Level Overall Low volume Moderate Volume High volume
Geographic region (%)
Northeast 4361 (23.1) 1655 (18.8) 1484 (21.6) 1222 (38.8)
south 6646 (35.3) 2996 (34.0) 2647 (38.5) 1003 (31.9)
Midwest 5403 (28.7) 2642 (29.9) 1838 (26.8) 923 (29.3)
West 2431 (12.9) 1531 (17.4) 900 (13.1) 0 (0.0)
Insurance (%)
private 6028 (32.0) 2694 (30.5) 2228 (32.4) 1106 (35.1)
Medicare 8696 (46.2) 4324 (49.0) 3069 (44.7) 1303 (41.4)
Medicaid 2369 (12.6) 1011 (11.5) 884 (12.9) 474 (15.1)
Uninsured 1096 (5.8) 510 (5.8) 417 (6.1) 169 (5.4)
Other/Missing 652 (3.5) 285 (3.2) 271 (3.9) 96 (3.0)
Distance to facility (%)
< 10 miles 9444 (50.1) 5004 (56.7) 3051 (44.4) 1389 (44.1)
10–19 miles 3860 (20.5) 1771 (20.1) 1488 (21.7) 601 (19.1)
20–49 miles 3044 (16.2) 1239 (14.0) 1225 (17.8) 580 (18.4)
≥ 50 miles 2454 (13.0) 796 (9.0) 1085 (15.8) 573 (18.2)
Unknown 39 (0.2) 14 (0.2) 20 (0.3) 5 (0.2)
Diagnosis (%)
Breast cancer 683 (3.6) 357 (4.0) 222 (3.2) 104 (3.3)
NscLc 14384 (76.3) 6597 (74.8) 5293 (77.1) 2494 (79.2)
scLc 3533 (18.8) 1757 (19.9) 1254 (18.3) 522 (16.6)
colon cancer 241 (1.3) 113 (1.3) 100 (1.5) 28 (0.9)
Year of diagnosis (%)
2010 2723 (14.5) 1323 (15.0) 993 (14.5) 407 (12.9)
2011 2852 (15.1) 1340 (15.2) 1034 (15.1) 478 (15.2)
2012 2994 (15.9) 1342 (15.2) 1143 (16.6) 509 (16.2)
2013 3264 (17.3) 1493 (16.9) 1189 (17.3) 582 (18.5)
2014 3460 (18.4) 1607 (18.2) 1271 (18.5) 582 (18.5)
2015 3548 (18.8) 1719 (19.5) 1239 (18.0) 590 (18.7)
Palliative care (%)
palliative care 7287 (38.7) 3488 (39.5) 2644 (38.5) 1155 (36.7)
No palliative care 11,552 (61.3) 5336 (60.5) 4224 (61.5) 1992 (63.3)
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Figure 3. Forest plots, risk of Death from Brain Metastases. hazard ratio for risk of death in the univariate cox models. Box 
size is proportional to population in each group. A. Variables associated with decreased risk of death relative to the reference 
level. b. Variables associated with increased risk of death relative to the reference level
a
B
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er risk than those in the Northeast and West (11% 
and 12%, respectively, compared to Northeast).
We used a random survival forest approach to 
determine variables most influential on survival. 
After entering hospital volume, we sequentially 
tested variables with the strongest association with 
survival (Fig. 2) to generate a multivariable model 
including Hospital volume, age (continuous), in-
surance type, Charlson-Deyo score, sex, facility 
type, race, receipt of palliative care and income. 
Mortality was 5% lower in high-volume centers 
(p = 0.039) compared with low-volume centers, 
after adjusting for the effects of sex, race, insurance 
status, income, facility type, Charlson-Deyo score, 
and receipt of palliative care (Tab. 2). In the final 
multivariable model subjects treated in community 
cancer centers were at 29% increased risk of death 
compared to those treated at academic centers and 
table 2. Multivariable Model for factors associated with risk of death from brain metastases (n = 18,841) 
Term Levels N HR (95% CI) p-value
Hospital volume
Low volume (ref ) 8824
Moderate volume 6869 0.97 (0.94 ,1.01) 0.162
high volume 3148 0.95 (0.91 ,10) 0.039
Facility type
academic (ref ) 7392
Integrated Network cancer 2487 1.06 (1.01 ,1.12) 0.014
comprehensive cancer center 7610 1.17 (1.13 ,1.22) < 0.001
community cancer center 1352 1.29 (1.21 ,1.38) < 0.001
age 18841 1.02 (1.02 ,1.02) < 0.001
Insurance type
private (ref ) 6028
Medicare 8696 1.09 (1.05 ,1.14) < 0.001
Medicaid 2369 1.19 (1.13 ,1.26) < 0.001
Uninsured 1096 1.30 (1.21 ,1.39) < 0.001
Other/Missing 652 1.20 (1.1 ,1.31) < 0.001
charlson-Deyo score
scOre 0 (ref ) 11853
scOre1 4749 1.13 (1.09 ,1.17) < 0.001
scOre2 2239 1.25 (1.19 ,1.31) < 0.001
sex
Male (ref ) 9479
Female 9362 0.83 (0.8 ,0.85) < 0.001
race/hispanic
Nh White (ref ) 14826
Nh Black 2565 0.93 (0.89 ,0.98) 0.004
hispanic 630 0.74 (0.68 ,0.81) < 0.001
asian/pacific Islander 608 0.73 (0.66 ,0.80) < 0.001
Other/Unknown 212 0.87 (0.75 ,1.01) 0.067
Annual income
> 46,000 UsD (ref ) 6219
30,000–45,999 UsD 8892 1.11 (1.07 ,1.15) < 0.001
< 30,000 UsD 3204 1.10 (1.05 ,1.16) < 0.001
Missing 526 0.92 (0.83 ,1.01) 0.072
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those treated in comprehensive cancer centers were 
at 17% increased risk of death. After multivariable 
adjustment, uninsured were at 30% increased risk 
of death, while those on Medicaid were at 19% 
increased risk. After adjusting for age, those with 
Medicare were at 9% increased risk of death (com-
pared with 47%, unadjusted risk). Those who did 
not receive palliative care were at 25% decreased 
risk of death compared with those receiving pal-
liative care.
Discussion 
The role of hospital and provider volume as 
a pre-treatment predictor of post-treatment mor-
bidity and mortality has become increasingly im-
portant due to the unsustainable growth in health-
care costs. Over the past decade, such investigation 
has expanded from the surgical realm (where for 
example it has been established that surgeons per-
forming fewer than three acoustic neuroma surger-
ies annually yield significantly increased in-hos-
pital operative morbidity and mortality) to radia-
tion therapy, where hospitals treating fewer than 
six cervical cancer cases with RT annually yield 
inferior survival [1, 7]. The goal of this study was 
to expand this important aspect of patient care in-
vestigation to brain metastases, the most common 
central nervous system malignancy, by examining 
patients with primary tumors comprising some of 
the most common cancer site causes of brain me-
tastases (lung, breast, colorectal). 
Our findings indicate that brain metastases pa-
tients receiving RT from hospitals performing few-
er than 12 brain RT per year (fewer than one per 
month) have inferior survival compared to those 
treated at hospitals performing at least one brain 
RT per month. While certain patient characteris-
tics were predictably associated with survival (race, 
income and comorbidities), most striking was that 
hospital volume itself remained significantly pre-
dictive of survival even after all of these character-
istics were accounted for. Such a result only high-
lights the necessity of ensuring that any patient with 
metastatic brain disease is appropriately triaged to 
high-volume centers.  Noteworthy is that there is 
a substantial overlap between hospital volume and 
academic centers; as demonstrated in Table 1, aca-
demic centers were more likely than non-academic 
centers to be moderate-volume (45.7% vs. 30.1%) 
or high-volume (31.5% vs. 3.2%), and survival 
rates were significantly higher in academic centers 
(p < 0.001 on univariate and multivariable analysis). 
Limitations of this study include the possibilities 
of incomplete/biased data reporting and/or mis-
coding during data submission to NCDB, and its 
retrospective nature. While NCDB contains several 
important details, important treatment variables, 
such as Karnofsky performance status or delinea-
tion of comorbidities beyond the Charlson/Deyo 
score, were unavailable; these represent limitations 
of the source data, in addition to the absence of 
melanoma and renal cell cancer patients in this 
analysis. As with all work derived from the NCDB, 
this study is derived from predominantly Commis-
sion on Cancer-approved hospitals; this skews the 
data towards hospitals more likely to be affiliated 
with a medical school/residency program, more 
likely to offer oncology-related services (chemo-
therapy, radiation therapy, screening programs, 
hospice/palliative care), less likely to be critical ac-
cess hospitals, more frequently located in urban 
locations, and more likely to have more total beds 
than non-approved hospitals comprising more than 
70% of hospitals in the American Hospital Associa-
tion Annual Survey Database [12]. 
conclusion
Hospitals performing on average one brain RT 
procedure per month show increased survival for 
brain metastases patients receiving radiation than 
those treated in lower volume hospitals. This finding, 
independent of additional demographic and disease 
characteristics, suggests the increased experience 
associated with increased volume improves patient 
table 2. Multivariable Model for factors associated with risk of death from brain metastases (n = 18,841) 
Term Levels N HR (95% CI) p-value
Palliative care
palliative (ref ) 7287
Not palliative care 11552 0.75 (0.73 ,0.78) < 0.001
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survival. Patients with brain metastases should be 
strongly considered by their providers for referral to 
high-volume centers in order to optimize their care. 
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